HIV

#Biologics / Biotechnology #CAR-T #China #CRISPR #Drug discovery #Gene editing #Genetics / genomics #HIV #HPV #Oncology #Pharmacology #T cell activation #The Dose

The Dose: DDW’s drug discovery highlights

DDW highlights the most interesting global news and comments within the drug discovery and development sector this month.   Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening… Read More

#Exclusive Content

#Boehringer Ingelheim #Cancer research #Collaboration #Diabetes #Drug development #Drug discovery #Eli Lilly #HIV #Lung cancer #Neurodevelopmental disorders #Precision medicine #Rare disease

This week in drug discovery (5-9 December)

News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been… Read More

#News

HIV vaccine
#Antibodies #HIV #mRNA-based vaccines #Phase I trial

Encouraging trial findings renew hope for HIV vaccine

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial.  In a paper published in Science, the researchers reveal critical new insights… Read More

#News #Trending News

HIV cell and antibodies
#Antibodies #Antivirals #HIV

Trial results support potential new therapeutic approach to HIV 

Positive study findings for N6LS, an investigational, broadly neutralising antibody (bNAb), could indicate a potential new approach for the treatment of HIV.  ViiV Healthcare, a specialist HIV company owned by GSK, Pfizer and Shionogi, presented positive findings from its Phase IIa proof-of-concept study of N6LS at the… Read More

#News

#Covid-19 #Drug Discovery 2022 #ELRIG #HIV #Neurology

This week in drug discovery (1-5 August)

News round-up by DDW’s Reece Armstrong for 1-5 August Research paves way for easier brain tumour diagnosis New research could pave the way to the earlier diagnosis of brain tumours through the development of a simple blood test for glioblastomas. IFC invests $30 million to improve healthcare in… Read More

#News

#Drug targets #HIV

New insights into HIV latent cells yield potential cure targets

In a presentation at AIDS 2022, the 24th International AIDS Conference in Montreal, scientists with the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) and their collaborators described how their use of technology revealed insights into cellular reservoirs of HIV and what those observations could mean… Read More

#News

#Appointment #Cell and gene therapy #Covid-19 #Diversity #HIV #Vaccines

This week in drug discovery (20-24 June)

News round-up by DDW’s Reece Armstrong for 20-24 June. Covid-19 vaccine development and research, gene therapies for dementia and a ‘game-changing’ treatment for HIV are some of the themes of this week’s news round-up. Moderna to set up mRNA vaccine centre in UK  Pharmaceutical company Moderna is to set-up… Read More

#News

#CRISPR #Genetic editing #HIV

Researchers target one-time treatment for HIV  

A one-time treatment for HIV and AIDS may be possible thanks to gene editing, according to research conducted by scientists from Tel Aviv University (TAU).   Researchers from Tel Aviv University used CRISPR systems to engineer type B white blood cells into producing HIV-neutralising antibodies in the immune… Read More

#News

#Drug approvals #HIV #Regulatory

Long acting HIV treatment receives approval in Japan  

Pharmaceutical company ViiV Healthcare has been granted Japanese approval for its treatment of HIV-1 as a combination therapy.   The approval comes from the Ministry of Health, Labour and Welfare (MHLW) in Japan and enables the company’s Vocabria (cabotegravir injection and tablets) to be used in combination… Read More

#News

#Covid-19 #HIV #Immunology / Virology & Vaccines

ReiThera and Exothera collaborate to develop vaccines for Africa

Biotech company ReiThera is collaborating with contract development and manufacturing organisation (CDMO) Exothera on a project to develop Covid-19 and HIV vaccines for low-and middle-income countries (LMIC). The collaboration will see the companies develop and deliver new low-cost vaccines based on ReiThera’s GRAd technology platform for LMICs in Africa. Exothera… Read More

#News

#Clinical trials #Covid-19 #Healthcare #HIV #Malaria #Public health

World Health Day: We celebrate global drug discovery

As we celebrate World Health Day, Lu Rahman looks at some of the key drug discovery and development successes over the last year that have significantly helped improved the health and wellbeing of the global population.   Malaria breakthroughs  According to The World Health Organization (WHO) more than a million people in Africa… Read More

#Editor's Choice #Exclusive Content #News

#HIV #Research study

Can tomato concentrate reduce inflammation associated with HIV? 

New UCLA-led research in mice suggests that adding a certain type of tomato concentrate to the diet can reduce the intestinal inflammation that is associated with HIV. Left untreated, intestinal inflammation can accelerate arterial disease, which in turn can lead to heart attack and stroke. The study is published… Read More

#News

#Antibodies #Clinical trials #HIV #Immunology / Virology & Vaccines #mRNA

Experimental mRNA HIV vaccine is safe and shows promise in animals 

An experimental HIV vaccine based on mRNA shows promise in mice and non-human primates, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results The results, published in Nature Medicine, show that the novel vaccine was safe and… Read More

#News

#Clinical trials #Data #FDA #HIV

HIV prevention options expanded in the US 

The US Food and Drug Administration (FDA) has approved a long-acting HIV prevention medication for the first time.   The drug  Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months. The FDA has approved the medicine for use by adults and adolescents weighing… Read More

#News #Trending News

#Clinical trials #HIV #Immunology / Virology & Vaccines #Johnson & Johnson

J&J HIV vaccine candidate does not protect women against HIV infection 

An investigational HIV vaccine tested in the “Imbokodo” clinical trial conducted in sub-Saharan Africa did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. It posed no safety concerns. The Phase IIb proof-of-concept study, which began in November 2017, enrolled 2,637 women… Read More

#News #Trending News